ANIK on Nasdaq
Anika Therapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with ORASURE TECHNOLOGIES INC, Intersect ENT or Beta Bionics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
56.6%Gross margin3
-9.8%Operating margin3
-9.6%Net margin3
-5.9%Revenue growth, 20253
-7.6%Return on equity3
$4.4MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
OEM Channel brought in 57% of the revenue Anika Therapeutics, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| OEM Channel | $84.6M | $77.8M | $64.4M |
| Commercial Channel | $36.1M | $42.1M | $48.4M |
Regions
United States brought in 62% of the revenue Anika Therapeutics, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $86.9M | $82.4M | $70.1M |
| Europe | $17.3M | $19.4M | $22.2M |
| Other Location | $16.6M | $18.1M | $20.5M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue39¢$49.0M
- Research and development21¢$25.8M
- Selling, general and admin39¢$49.1M
- Income tax1¢$672.0K
Out of $112.8M in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending42¢$6.8M
- Share buybacks58¢$9.5M
Out of $11.2M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M |
| Cost of revenue | $49.0M | $43.9M | $38.3M |
| Gross profit | $63.8M | $76.0M | $82.5M |
| Research & development | $25.8M | $25.5M | $21.8M |
| Selling, general & administrative | $49.1M | $55.6M | $59.9M |
| Total operating expenses | $74.9M | $81.1M | $81.7M |
| (Loss) income from operations | -$11.1M | -$5.1M | $844.0K |
| Interest and other income, net | $1.7M | $2.3M | $2.3M |
| (Loss) income before income taxes | -$9.3M | -$2.8M | $3.2M |
| Provision for income taxes | $672.0K | $6.1M | $6.6M |
| Loss from continuing operations | -$10.0M | -$8.8M | -$3.4M |
| Loss from discontinued operations, net of tax | -$901.0K | -$47.6M | -$79.2M |
| Continuing operations (in dollars per share) | -$1 | -$1 | -$0 |
| Discontinued operations (in dollars per share) | -$0 | -$3 | -$5 |
| Earnings Per Share, Basic | -$0.76 | -$3.83 | -$5.64 |
| Continuing operations (in dollars per share) | -$1 | -$1 | -$0 |
| Discontinued operations (in dollars per share) | -$0 | -$3 | -$5 |
| Earnings Per Share, Diluted | -$0.76 | -$3.83 | -$5.64 |
| Basic (in shares) | 14.3M shares | 14.7M shares | 14.7M shares |
| Diluted (in shares) | 14.3M shares | 14.7M shares | 14.7M shares |
| Net loss | -$10.9M | -$56.4M | -$82.7M |
| Foreign currency translation adjustment | $1.8M | -$840.0K | $500.0K |
| Comprehensive loss | -$9.1M | -$57.2M | -$82.2M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $57.5M | $55.6M | |
| Accounts receivable, net | $23.7M | $23.6M | |
| Inventories | $18.8M | $23.8M | |
| Prepaid expenses and other current assets | $3.4M | $5.5M | |
| Current assets held for sale | $0 | $5.1M | |
| Total current assets | $103.4M | $113.7M | |
| Property and equipment, net | $40.3M | $39.0M | |
| Right-of-use assets | $25.9M | $25.7M | |
| Other long-term assets | $4.0M | $5.7M | |
| Notes receivable | $5.6M | $5.9M | |
| Deferred tax assets | $1.3M | $1.2M | |
| Intangible assets, net | $1.6M | $2.5M | |
| Goodwill | $8.1M | $7.1M | $7.6M |
| Non-current assets held for sale | $0 | $2.0M | |
| Total assets | $190.3M | $202.7M | |
| Accounts payable | $6.0M | $5.6M | |
| Accrued expenses and other current liabilities | $15.9M | $13.6M | |
| Current liabilities held for sale | $0 | $4.1M | |
| Total current liabilities | $21.9M | $23.3M | |
| Other long-term liabilities | $701.0K | $772.0K | |
| Lease liabilities | $24.2M | $24.0M | |
| Non-current liabilities held for sale | $0 | $659.0K | |
| Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024, respectively | $0 | $0 | |
| Common stock, $.01 par value; 90,000 shares authorized, 15,385 issued and 13,889 outstanding and 15,010 shares issued and 14,416 outstanding at December 31, 2025 and 2024, respectively | $139.0K | $144.0K | |
| Additional paid-in-capital | $87.5M | $89.0M | |
| Accumulated other comprehensive loss | -$5.0M | -$6.8M | |
| Retained earnings | $60.8M | $71.7M | |
| Total stockholders equity | $143.5M | $154.0M | $212.3M |
| Total liabilities and stockholders equity | $190.3M | $202.7M | |
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Preferred stock, shares authorized (in shares) | 1.2M shares | 1.2M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Common stock shares authorized (in shares) | 90.0M shares | 90.0M shares | |
| Common stock, shares issued (in shares) | 15.4M shares | 15.0M shares | |
| Common stock, shares outstanding (in shares) | 13.9M shares | 14.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$10.9M | -$56.4M | -$82.7M |
| Depreciation | $5.4M | $6.9M | $6.4M |
| Amortization of acquisition related intangible assets | $357.0K | $1.2M | $7.8M |
| Non-cash operating lease cost | $2.1M | $2.1M | $2.2M |
| (Gain) loss on sale of assets | -$166.0K | $2.9M | $1.9M |
| Loss on impairment of long-lived assets | $0 | $2.5M | $62.2M |
| Stock-based compensation expense | $10.1M | $13.1M | $15.2M |
| Deferred income taxes | -$7.0K | $260.0K | -$6.3M |
| Provision for doubtful accounts | $265.0K | $1.2M | $190.0K |
| Provision for inventory | $5.8M | $44.7M | $3.3M |
| Interest income on notes receivable | -$896.0K | $0 | $0 |
| Accounts receivable | $408.0K | $3.4M | -$1.3M |
| Inventories | $30.0K | -$9.4M | -$11.4M |
| Prepaid expenses, other current and long-term assets | $2.3M | $558.0K | $560.0K |
| Accounts payable | $42.0K | -$2.5M | -$11.0K |
| Operating lease liabilities | -$2.0M | -$2.1M | -$2.1M |
| Accrued expenses, other current and long-term liabilities | -$1.5M | -$3.7M | $1.6M |
| Income taxes | -$134.0K | $665.0K | $530.0K |
| Net cash provided by (used in) operating activities | $11.2M | $5.4M | -$1.8M |
| Purchases of property and equipment | -$6.8M | -$7.7M | -$5.4M |
| Proceeds from sale of Parcus | $4.5M | $0 | $0 |
| Notes receivable | $1.3M | $0 | $0 |
| Proceeds from sale of intangible assets | $600.0K | $0 | $0 |
| Acquisition of intangible assets | $0 | -$600.0K | $0 |
| Net cash used in investing activities | -$401.0K | -$8.3M | -$5.4M |
| Repurchases of common stock | -$9.5M | -$10.9M | -$5.0M |
| Proceeds from employee stock purchase program | $500.0K | $708.0K | $805.0K |
| Cash paid for tax withheld on vested restricted stock awards | -$1.6M | -$2.6M | -$2.2M |
| Proceeds from exercises of equity awards | $0 | $76.0K | $23.0K |
| Net cash used in financing activities | -$10.6M | -$12.7M | -$6.3M |
| Exchange rate impact on cash | $86.0K | -$48.0K | $79.0K |
| Decrease in cash and cash equivalents | $322.0K | -$15.7M | -$13.5M |
| Cash paid for income taxes, net of refunds | $1.1M | $4.0M | $3.1M |
| Right-of-use assets obtained in exchange for operating lease liabilities | $2.8M | $3.3M | |
| Purchases of property and equipment included in accounts payable and accrued expenses | $666.0K | $639.0K | $815.0K |
| Notes receivable | $0 | $5.9M | $0 |
Former names
Recent filings
- Aug 7, 2026144
- Aug 5, 20264
- Jul 31, 2026SCHEDULE 13G/A
- Jul 29, 20268-K
- Jul 29, 202610-Q
- Jul 29, 2026S-8
- Jul 17, 2026SCHEDULE 13G/A
- Jul 14, 20268-K
- Jun 23, 20268-K
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 8, 2026DEFA14A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10